For those aged 75 to 84 years, LIS receipt linked to increased odds of receiving immunomodulatory drugs
New research has identified as few as nine genetic features would need to be tested to identify high-risk patients who might benefit from intensive myeloma treatment.
Survival gains observed when elotuzumab was added to treatment.
Improved progression-free survival in relapsed multiple myeloma has been seen with the addition of carfilzomib to lenalidomide and dexamethasone therapy.
Recent therapeutic progress has improved outcomes for patients with myeloma; however, the complex biology of this disease continues to challenge treatment.
New multiple myeloma treatment options have shown promise for patients aged 65 years and younger and for newly diagnosed individuals ineligible for stem-cell transplantation, according to two studies.
Lenalidomide plus dexamethasone delays progression, improves survival versus observation
Carfilzomib is approved for people who have been treated with at least two other therapies.
Bortezomib induction/maintenance up complete response, progression-free, and overall survival rates.
These tips can help patients with multiple myeloma learn more about how to cope with the disease.
Three studies show benefit of lenalidomide, including after induction therapy or stem-cell transplant.
The urgent need for treatment may require a woman with a hematologic cancer to end an early-stage pregnancy, but not necessarily a later-stage one.
This fact sheet reviews a number of resources available to patients coping with multiple myeloma, from the health care team to in the community.
Although the risks of erythropoietin-stimulating agents can outweigh the benefits, select patients may benefit.
Many people see their cancer care as a collaboration. This fact sheet provides tips for patients with multiple myeloma for improving communication with providers during office visits.
Overall, cancer incidence rates fell approximately 1% annually and overall death rates decreased by an average of 1.6% annually between 2003 and 2007.
Sign Up for Free e-newsletters
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- A Witness to Letting Go: Nursing Care at the End of Life
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Ciprofloxacin Plus Doxycycline Reduces Infection Rate in Multiple Myeloma Post-ASCT
- Prognostic Significance of Epidermal Growth Factor Receptor Expression in Glioma Patients
- Fathers Can Pass Inherited Ovarian Cancer Risk to Daughters
- Modified XELIRI Noninferior to FOLFIRI for OS in Metastatic Colorectal Cancer
- Nabilone Improves Cancer-Associated Anorexia in Lung Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|